Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin inhaled spray for symptom control in hospitalized adults with COVID-19
IRCT20080901001165N50Phase 3Completed
- Sponsor
- Sina Darou
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azithromycin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Sina Darou. Primary endpoint: Clinical symptoms changes. Started May 2020; status: completed.
02
Drugs
azithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20080901001165N50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20080901001165N50.